Skip to main content
EJNMMI Research
Figure 3 | EJNMMI Research

Figure 3

From: Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Figure 3

The dose-ranging study (RO4987655, 1.0 to 5.0 mg/kg). Representative [18F] FDG-PET images of NCI-H2122 tumors xenografted in Balb nu/nu mice, treated with vehicle and RO4987655 and scanned on days 0, 1 and 3 after treatment. The one-mouse follow-up [18F] FDG-PET MIP images (upper panel) and corresponding transaxial sections (lower panel) performed on days 0, 1, and 3 after vehicle (a, b) and RO4987655, 5.0 mg/kg treatment (c, d). The transaxial tumor sections (b, d) show a plane of the mouse body that includes tumor (T). The same color scale was applied to all FDG-PET images after correction for injected dose per gram tissue,% ID/gr, to show the relative [18F] FDG uptake in the tissues.

Back to article page